A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients

We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. A systematic search of publications about randomized controlled trials (RCTs) focus...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiothoracic surgery Vol. 16; no. 1; p. 90
Main Authors Ouyang, Hang, Zeng, Xuehui, Zhang, Chunlei, Song, Linli, Xu, Jiarui, Hou, Zhihui, Xie, Siya, Tao, Zheng, He, Jincai
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 17.04.2021
BioMed Central
BMC
Subjects
Blood clot
Care and treatment
Clinical trials
Diabetes
Diabetes mellitus
Diabetics
Everolimus-eluting stent
Health aspects
Heart attack
Heart attacks
Implants
Lesions
Meta-analysis
Mortality
Myocardial infarction
Paclitaxel
Paclitaxel-eluting stents
Rapamycin
Sensitivity analysis
Sirolimus-eluting stents
Stent (Surgery)
Stents
Thromboembolism
Thrombosis
Diabetes
Paclitaxel-eluting stents
Everolimus-eluting stent
Sirolimus-eluting stents
Meta-analysis
Online AccessGet full text

Cover

Abstract We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). Among those three types of stents, EES should be the first recommended stent for DM patients.
AbstractList Abstract Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. Methods A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. Results EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) ( p  = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p  < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52–0.99, p  = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26–0.73, p  = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28–0.98, p  = 0.04) and PES (RR = 0.18, 95% CI: 0.07–0.51, p  = 0.001). Conclusion Among those three types of stents, EES should be the first recommended stent for DM patients.
Abstract Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. Methods A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. Results EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52–0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26–0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28–0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07–0.51, p = 0.001). Conclusion Among those three types of stents, EES should be the first recommended stent for DM patients.
Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. Methods A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. Results EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). Conclusion Among those three types of stents, EES should be the first recommended stent for DM patients. Keywords: Sirolimus-eluting stents, Paclitaxel-eluting stents, Everolimus-eluting stent, Diabetes, Meta-analysis
We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). Among those three types of stents, EES should be the first recommended stent for DM patients.
Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. Methods A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. Results EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52–0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26–0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28–0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07–0.51, p = 0.001). Conclusion Among those three types of stents, EES should be the first recommended stent for DM patients.
We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. A systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. EES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). Among those three types of stents, EES should be the first recommended stent for DM patients.
OBJECTIVEWe performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents (PES) should be preferred for the treatment of DM patients. METHODSA systematic search of publications about randomized controlled trials (RCTs) focused on diabetic patients received EES, SES or PES was conducted. We evaluated the following indicators: target vessel revascularization (TVR), target lesion revascularization (TLR), late luminal loss (LLL), stent thrombosis (ST), myocardial infarction (MI), all-cause mortality and cardiac mortality. RESULTSEES showed obvious advantages over SES for DM patients, as it induced the lowest rate of target vessel revascularization and target lesion revascularization (TLR) (p = 0.04). In addition, EES induced lower in-segment LLL than PSE and SES and lower in-stent LLL than PES in DM patients (all p < 0.05). Moreover, EES effectively reduced all-cause mortality compared to SES (RR = 0.71, 95% CI: 0.52-0.99, p = 0.04) and MI rates compared to PES (RR = 0.44, 95% CI: 0.26-0.73, p = 0.0002). Furthermore, EES could reduce the ST rate compared with both SES (RR = 0.53, 95% CI: 0.28-0.98, p = 0.04) and PES (RR = 0.18, 95% CI: 0.07-0.51, p = 0.001). CONCLUSIONAmong those three types of stents, EES should be the first recommended stent for DM patients.
ArticleNumber 90
Audience Academic
Author Xie, Siya
Tao, Zheng
Ouyang, Hang
Zeng, Xuehui
Hou, Zhihui
Zhang, Chunlei
Song, Linli
Xu, Jiarui
He, Jincai
Author_xml – sequence: 1
  givenname: Hang
  surname: Ouyang
  fullname: Ouyang, Hang
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 2
  givenname: Xuehui
  surname: Zeng
  fullname: Zeng, Xuehui
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 3
  givenname: Chunlei
  surname: Zhang
  fullname: Zhang, Chunlei
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 4
  givenname: Linli
  surname: Song
  fullname: Song, Linli
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 5
  givenname: Jiarui
  surname: Xu
  fullname: Xu, Jiarui
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 6
  givenname: Zhihui
  surname: Hou
  fullname: Hou, Zhihui
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 7
  givenname: Siya
  surname: Xie
  fullname: Xie, Siya
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China
– sequence: 8
  givenname: Zheng
  surname: Tao
  fullname: Tao, Zheng
  email: taozheng67@foxmail.com
  organization: Department of Vascular Surgery, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang, Jiangsu, 212001, People's Republic of China. taozheng67@foxmail.com
– sequence: 9
  givenname: Jincai
  surname: He
  fullname: He, Jincai
  email: sztcmhjc@163.com
  organization: Department of Clinical Laboratory, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong, 518033, People's Republic of China. sztcmhjc@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33865413$$D View this record in MEDLINE/PubMed
BookMark eNp1Uk1rFDEYDlKxH_oHPMiAFy9T8zmTXISlaC0UvOg55GvWLJlkTWaKPfnXzey2ZbcoOSS8z8ebN3nOwUlM0QHwFsFLhHj3sSACkWghRi1ElOGWvwBnqKei5VDAk4PzKTgvZQMhZQSyV-CUEN4xisgZ-LNqRjepVkUV7osvTRoad-dyCn6cS-vCPPm4bsrk4lSaCpS5NMX_B1fRNltlgp_Ubxeeoz421ivtJm8qa_JL8TV4OahQ3JuH_QL8-PL5-9XX9vbb9c3V6rY1rCNTayGjjlUtHphliGuBFaFGC804QYZb0XEDdT9AqxhW2lICnXGQk0WpBLkAN3tfm9RGbrMfVb6XSXm5K6S8lirXiwUne64RFpQ6ai0d-l5j2mtGteEIU8EWr097r-2sR2dNnSOrcGR6jET_U67TneSQ4Z7TavDhwSCnX7Mrkxx9MS4EFV2ai8QMMdgxxmClvn9G3aQ518_asSgWguED1lrVAXwcUu1rFlO56jpEUW27sC7_warLutGbmq3B1_qRAO8FJqdSshueZkRQLhGU-wjKGkG5i6DkVfTu8HWeJI-ZI38B3fnaZw
CitedBy_id crossref_primary_10_1097_JS9_0000000000000736
crossref_primary_10_1089_blr_2022_29259_cmh
crossref_primary_10_3390_jcm12237367
Cites_doi 10.1016/j.jacc.2011.07.031
10.1002/ccd.25875
10.1016/S0140-6736(09)62127-9
10.1161/CIRCULATIONAHA.110.015453
10.1016/j.amjcard.2007.05.038
10.4244/eij-d-17-00333
10.1161/CIRCULATIONAHA.108.829176
10.1007/s11886-017-0837-y
10.1016/S0735-1097(00)00732-4
10.1002/9780470712184
10.1001/jama.299.16.1903
10.1093/eurheartj/ehn434
10.1136/hrt.2005.075960
10.1016/j.jcin.2014.02.016
10.1056/NEJMoa044372
10.1016/S0140-6736(03)14462-5
10.1161/01.CIR.0000153356.72810.97
10.1093/eurheartj/ehn021
10.1002/ccd.24741
10.1016/j.jacc.2007.10.034
10.1161/CIRCINTERVENTIONS.114.002319
10.1016/j.ijcard.2016.12.116
10.1016/j.jacc.2004.01.045
10.1016/j.ahj.2012.02.006
10.1016/j.jacc.2007.07.084
10.1056/NEJMoa051175
10.1016/j.amjcard.2012.07.022
10.1007/s00395-011-0177-9
10.1016/j.jacc.2010.10.006
10.1136/bmj.e5170
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID NPM
AAYXX
CITATION
3V.
7X7
7XB
88E
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
K9.
M0S
M1P
M7Z
P64
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13019-021-01452-8
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
AUTh Library subscriptions: ProQuest Central
ProQuest One Community College
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biochemistry Abstracts 1
Biotechnology and BioEngineering Abstracts
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Technology Research Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Biochemistry Abstracts 1
Engineering Research Database
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef


PubMed
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 1749-8090
EndPage 90
ExternalDocumentID oai_doaj_org_article_78b12944e4dd4f77b247b54bc8124959
A661412780
10_1186_s13019_021_01452_8
33865413
Genre Journal Article
GrantInformation_xml – fundername: Shenzhen Science and Technology Project
  grantid: JCYJ20170307155244629
– fundername: Guangdong Province Traditional Chinese Medicine Bureau Project
  grantid: 20182125
– fundername: ;
  grantid: JCYJ20170307155244629
– fundername: ;
  grantid: 20182125
GroupedDBID ---
-5E
-5G
-A0
-BR
0R~
29K
2WC
3V.
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
P6G
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
~8M
AAYXX
CITATION
ABVAZ
AFGXO
AFNRJ
7XB
8FD
8FK
AZQEC
DWQXO
FR3
K9.
M7Z
P64
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c563t-d054e5abe2f5d518b92a34cb9b5831c8d968c0b7f0da52abd430ece083d054a93
IEDL.DBID RPM
ISSN 1749-8090
IngestDate Sun Sep 29 07:14:44 EDT 2024
Tue Sep 17 21:06:31 EDT 2024
Fri Aug 16 05:48:35 EDT 2024
Fri Sep 13 10:14:14 EDT 2024
Thu Feb 22 23:27:32 EST 2024
Fri Feb 02 04:31:58 EST 2024
Thu Sep 12 19:52:32 EDT 2024
Sat Sep 28 08:27:48 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Diabetes
Paclitaxel-eluting stents
Everolimus-eluting stent
Sirolimus-eluting stents
Meta-analysis
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-d054e5abe2f5d518b92a34cb9b5831c8d968c0b7f0da52abd430ece083d054a93
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052784/
PMID 33865413
PQID 2514299520
PQPubID 55047
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_78b12944e4dd4f77b247b54bc8124959
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8052784
proquest_miscellaneous_2515065550
proquest_journals_2514299520
gale_infotracmisc_A661412780
gale_infotracacademiconefile_A661412780
crossref_primary_10_1186_s13019_021_01452_8
pubmed_primary_33865413
PublicationCentury 2000
PublicationDate 2021-04-17
PublicationDateYYYYMMDD 2021-04-17
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-17
  day: 17
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of cardiothoracic surgery
PublicationTitleAlternate J Cardiothorac Surg
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References 1452_CR10
1452_CR11
PW Serruys (1452_CR17) 2006; 2
P Codner (1452_CR1) 2017; 19
1452_CR30
1452_CR9
1452_CR8
KE Kip (1452_CR31) 2008; 51
1452_CR6
1452_CR18
E Di Lorenzo (1452_CR16) 2014; 7
1452_CR5
1452_CR14
1452_CR4
1452_CR13
1452_CR3
1452_CR2
1452_CR15
1452_CR21
1452_CR20
1452_CR23
1452_CR22
E Grube (1452_CR7) 2012; 163
T Hammoud (1452_CR19) 2000; 36
WJ Kim (1452_CR12) 2011; 124
1452_CR29
1452_CR28
1452_CR25
1452_CR24
1452_CR27
1452_CR26
References_xml – ident: 1452_CR6
  doi: 10.1016/j.jacc.2011.07.031
– ident: 1452_CR14
  doi: 10.1002/ccd.25875
– ident: 1452_CR5
  doi: 10.1016/S0140-6736(09)62127-9
– volume: 124
  start-page: 886
  year: 2011
  ident: 1452_CR12
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.110.015453
  contributor:
    fullname: WJ Kim
– ident: 1452_CR3
  doi: 10.1016/j.amjcard.2007.05.038
– ident: 1452_CR15
  doi: 10.4244/eij-d-17-00333
– ident: 1452_CR4
  doi: 10.1161/CIRCULATIONAHA.108.829176
– volume: 19
  start-page: 28
  issue: 4
  year: 2017
  ident: 1452_CR1
  publication-title: Curr Cardiol Rep
  doi: 10.1007/s11886-017-0837-y
  contributor:
    fullname: P Codner
– volume: 36
  start-page: 355
  issue: 2
  year: 2000
  ident: 1452_CR19
  publication-title: J Am Coll Cardiol
  doi: 10.1016/S0735-1097(00)00732-4
  contributor:
    fullname: T Hammoud
– ident: 1452_CR8
  doi: 10.1002/9780470712184
– ident: 1452_CR18
  doi: 10.1001/jama.299.16.1903
– ident: 1452_CR20
  doi: 10.1093/eurheartj/ehn434
– ident: 1452_CR2
  doi: 10.1136/hrt.2005.075960
– volume: 7
  start-page: 849
  issue: 8
  year: 2014
  ident: 1452_CR16
  publication-title: JACC Cardiovasc Interv
  doi: 10.1016/j.jcin.2014.02.016
  contributor:
    fullname: E Di Lorenzo
– ident: 1452_CR21
  doi: 10.1056/NEJMoa044372
– ident: 1452_CR27
  doi: 10.1016/S0140-6736(03)14462-5
– ident: 1452_CR28
  doi: 10.1161/01.CIR.0000153356.72810.97
– ident: 1452_CR22
  doi: 10.1093/eurheartj/ehn021
– ident: 1452_CR13
  doi: 10.1002/ccd.24741
– volume: 51
  start-page: 701
  issue: 7
  year: 2008
  ident: 1452_CR31
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2007.10.034
  contributor:
    fullname: KE Kip
– ident: 1452_CR10
  doi: 10.1161/CIRCINTERVENTIONS.114.002319
– volume: 2
  start-page: 286
  year: 2006
  ident: 1452_CR17
  publication-title: EuroIntervention
  contributor:
    fullname: PW Serruys
– ident: 1452_CR30
  doi: 10.1016/j.ijcard.2016.12.116
– ident: 1452_CR26
  doi: 10.1016/j.jacc.2004.01.045
– volume: 163
  start-page: 867
  year: 2012
  ident: 1452_CR7
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2012.02.006
  contributor:
    fullname: E Grube
– ident: 1452_CR29
  doi: 10.1016/j.jacc.2007.07.084
– ident: 1452_CR25
  doi: 10.1056/NEJMoa051175
– ident: 1452_CR11
  doi: 10.1016/j.amjcard.2012.07.022
– ident: 1452_CR23
  doi: 10.1007/s00395-011-0177-9
– ident: 1452_CR9
  doi: 10.1016/j.jacc.2010.10.006
– ident: 1452_CR24
  doi: 10.1136/bmj.e5170
SSID ssj0045305
Score 2.2823355
Snippet We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting stents...
Abstract Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and...
Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting...
OBJECTIVEWe performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and paclitaxel eluting...
Abstract Objective We performed this meta-analysis to determine which stent among everolimus eluting stents (EES), sirolimus eluting stents (SES) and...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 90
SubjectTerms Blood clot
Care and treatment
Clinical trials
Diabetes
Diabetes mellitus
Diabetics
Everolimus-eluting stent
Health aspects
Heart attack
Heart attacks
Implants
Lesions
Meta-analysis
Mortality
Myocardial infarction
Paclitaxel
Paclitaxel-eluting stents
Rapamycin
Sensitivity analysis
Sirolimus-eluting stents
Stent (Surgery)
Stents
Thromboembolism
Thrombosis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yJy-i-FVdJYLgQcK2ab56fIrLIujJhb2FfFULu31i-2Bv_uvOJH2PV0W8eCp0JpBmfvNVMjOEvJatUuC2Emt47ZkQUTKfkme88-AtQ6-cxkLhT5_VxaX4eCWvjkZ94Z2w0h64HNyZNh5ckhBJxCh6rT0X2kvhg8ljk0vpXiP3yVSxwUICjPclMkadTWCpsViHY-osJNiAlRvK3fr_tMlHTml9YfLIA53fJ_eW0JFuypYfkDtpfEh-buhNmh1zS3MRuu1pAnhur4eb3cQSAmv8SkGW4zxRvIOxm-g0_IXuxkghicbG3bfp-nfqMNLyq3YIdOnHOj0il-cfvry_YMtQBRakamcWIUZLEnh5L6NsjO-4a0XwnZembYKJnTKh9rqvo5Pc-SjaOoUEkRqudF37mJyM2zE9JdR0RgVVR8ivvUhBdrXTBp5N7XwLhrQib_dnbL-X3hk25xxG2SIRCxKxWSIWuN-hGA6c2Pc6vwA02AUN9l9oqMgbFKJF7QRJBbcUGcCGsc-V3WA40nBt6oqcrjhBq8KavIeBXbR6shALovuWHMivDmRciTfVxrTdZR4JYR0kfhV5UlBz-KQWB6xC1FARvcLT6pvXlHH4lnt-4-QJbcSz_3FIz8ldnlVBsEafkpP5xy69gNBq9i-zFv0C1KoiFw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Na9VAEF9qe_Eiil-pVVYQPMjyks1udnOSV2l5CBYRC70t-5UaaJPa5IE3_3Vn8vFsFD0FMhNIMr_52t2ZIeSNzIsC3FZkGU8dEyJI5mJ0jJcOvKWvCquwUPjTWbE5Fx8v5MUe2cy1MHiscraJg6EOrcc18hX4YTSdkqcr63AVwPer9zffGc6Pwn3WaZjGPXLAM4EbtgfHJ2efv8xWWUgA9lw0o4tVB7Yby3c4JtNCglVYOKahf__fVvqOm1oeobzjk04fkgdTMEnXo_Qfkb3YPCY_1_Q69pbZqd0IbSsaAbDtVX297VhEqDWXFKTb9B3FUxnbjnb1P-i2CRTSamzl_SNe_UmtGzou3taeTh1auyfk_PTk64cNm8YsMC-LvGcBorYogZdXMshMu5LbXHhXOqnzzOtQFtqnTlVpsJJbF0SeRh8hdsMnbZk_JftN28TnhOpSF75IA2TcTkQvy9QqDdcstS4H05qQd_M_NjdjNw0zZCG6MKNEDEjEDBIxwH2MYthxYifs4UZ7e2kmxTJKOwhZhIgiBFEp5bhQTgrn9TBWu0zIWxSiQX1F1Nip7ABeGDtfmTUGKBlXOk3I0YIT9MwvyTMMzKTnnfmNyoS83pHxSTy71sR2O_BICPQgFUzIsxE1u0_KceQqxBEJUQs8Lb55SWnqb0MXcJxFobQ4_P9rvSD3-QBywTJ1RPb72218CWFU715NGvILsXMflQ
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA_revEiil_VVSIIHiTapvnqQeQpLouwnnywt5CvroW37fraB-vJf91J2j62unoqdCbQZn6T-U2bzCD0ipdCQNgKpKC5JYx5TmwIltDKQrR0tTAyHhQ-_SpO1uzLGT87QHO7o2kC-xtTu9hPar3dvL368fMDOPz75PBKvOthHY5HcWhMjBkHD7-FblNWsoj4U7b_q8A4gHs-OHPjuEVwSjX8_16pr4Wq5TbKa3Hp-B66OxFKvBoRcB8dhPYB-rXCF2EwxEwlR3BX4wCg7TbNxa4nIcKtPcdg4XbocdyZsetx3_xDblqPIbWO5byvwuZPadPi8QNu4_BUpbV_iNbHn799OiFTqwXiuCgH4oG5BQ66tOaeF8pW1JTM2cpyVRZO-Uool1tZ595waqxnZR5cAP4WR5qqfIQO264NTxBWlRJO5B6ybsuC41VupIJrkRtbwvKaoTfzHOvLsaKGTpmIEnq0iAaL6GQRDdofoxn2mrEadrrRbc_15FxaKgu0hbHAvGe1lJYyaTmzTqXW2lWGXkcj6ogisJQz09EDeOBY_UqvIkkpqFR5ho4WmuBrbimeYaBnqGpgiDGocwril3txHBn3r7Wh2yUdDmQP0sEMPR5Rs3-lMrZdBS6RIbnA0-Kdl5K2-Z4qgcd-FFKxp_9_rGfoDk0gZ6SQR-hw2O7Cc6BSg32R_OM3aModow
  priority: 102
  providerName: Scholars Portal
Title A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
URI https://www.ncbi.nlm.nih.gov/pubmed/33865413
https://www.proquest.com/docview/2514299520/abstract/
https://search.proquest.com/docview/2515065550
https://pubmed.ncbi.nlm.nih.gov/PMC8052784
https://doaj.org/article/78b12944e4dd4f77b247b54bc8124959
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJCiWX0tKX23RRodBDcda2nj46ISEsbAhtA3sTkqxNDbt2iL3QW_96R7K9xC299LKGnRHYnm80M2bmE0KfGOEcwpaL0ywxMaUli41zJs5yA9HSrrkWflB4ec2vbulixVYHiI2zMKFp35rqtN5sT-vqR-itvN_a-dgnNr9ZnnsafiHp_BAdCkLGEr3ffikDBI_TMZLPW9ik_ZxO5qtmysD9j9FT4k-6pCmZBKPA2f_3zvwoNE3bJh_Focvn6NmQQOKiv9EX6MDVL9GvAm9dp2M9UIzgZo0dgLTZVNtdGzsPr_oOg0XrrsW-E2PX4rb6h1zXJYZS2tN3_3SbP6VVjfsPtpXFAytr-wrdXl58P7-Kh6MVYss46eISMjXHQDdbs5Kl0uSZJtSa3DBJUivLnEubGLFOSs0ybUpKEmcd5Gt-pc7Ja3RUN7V7i7DMJbc8KaHKNtRZlidaSLimiTYEttMIfRnfsbrvGTRUqDwkV71xFBhHBeMo0D7zZthrevbr8EfzcKcGDCghDaQplDpalnQthMmoMIwaK8NR2nmEPnsjKu-jYCmrh1EDuGHPdqUKn5SkAKEkQicTTfAtOxWPMFCDb7cKMkIfxFkG4o97sV_p-9Vq1-yCDoPkDsq_CL3pUbN_pBF8ERITPE2eeSoBRwjM3wPw3_33yvfoOAuuQONUnKCj7mHnPkBW1ZkZ-NJKzNCTolh8W8D17OL65ussfKOA3yWVs-BnvwH8milV
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,24346,27957,27958,31754,31755,33779,33780,43345,43840,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Na9RAdNDtQS-i-BWtOoLgQYbmYyYzOclWWlZtF5EWehvmK3WhTWqzC978676XTNZG0VMg7w3M5H1P3gchb0RRlmC2Asvy1DLOvWA2BMvyyoK1dHVpJBYKHy_LxSn_dCbO4oVbF9MqR53YK2rfOrwj3wM7jKpT5On7q-8Mp0bh39U4QuM22eEFhCozsrN_sPzyddTFXAA7j6UyqtzrQGNj0U6OITQXoAsm5qjv2v-3br5hnKaJkzcs0eF9ci-6kHQ-0PwBuRWah-TnnF6GtWEmNhmhbU0DsGl7sbrcdCwggzXnFGjarDuKuRibjnarf8BN4ykE09jA-0e4-BO6auhwZbtyNPZl7R6R08ODkw8LFocrMCfKYs08-GpBAG5eCy8yZavcFNzZygpVZE75qlQutbJOvRG5sZ4XaXABPDZcaariMZk1bROeEqoqVboy9RBnWx6cqFIjFTyz1NgCFGpC3o3fWF8NPTR0H3uoUg8U0UAR3VNEA_Y-kmGLif2v-xft9bmO4qSlsuCocB6497yW0uZcWsGtU_0w7Sohb5GIGqUUKOVMLDaADWO_Kz1HtyTLpUoTsjvBBOlyU_DIBjpKd6d_82JCXm_BuBIz1prQbnocAe4dBIAJeTJwzfZIBQ5aBe8hIXLCT5MzTyHN6lvf-xsnUEjFn_1_W6_IncXJ8ZE--rj8_JzczXuG5yyTu2S2vt6EF-BIre3LKC2_ANDpHsg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagSFUvLGILFDASEgfkmSx24hyHwqgsrXqgUsXF8pYSMZOMmkRCXPjrPDvJaFLEpadI856leN73tuj5M0JvWJKmkLYsieJQEUoNI8paReJcQbbURSozd1D45DQ9PqefL9jFzlVffmhfq3JWrdazqvzhZys3az0f58TmZydHjoY_43S-McX8NroDPhvnY6PeB2HKAMfjGRmezhsI1e60Tux6Z8ogCByg_cTdd0mjZJKSPHP_v_F5J0FNhyd3stHyHvo-7qMfQvk561o107-vUTzeaKP30d2hRsWLXuUBumWrh-jPAq9tK4kcWExwXWALflCvynXXEOsQXF1iAE3VNtgNe3QNbsr_yGVlMHTrjiH8l11dl5YV7r8JlxoPxK_NI3S-_Pjt6JgMtzcQzdKkJQaKQctANy6YYRFXeSwTqlWuGE8izU2ech2qrAiNZLFUhiah1RZKQrdS5sljtFfVlX2KMM95qtPQQCOvqNUsD2XG4RmFUiVg_QC9Gw0oNj1Jh_DNDU9Fb3kBlhfe8gK03zsbbzUdwbb_ob66FMO_LzKuoBKi1FJjaJFlKqaZYlRp7m_rzgP01iFEuDAAMNByOM0AL-wItcTC1T0RGC8M0OFEE9xXT8UjxsQQPhoBRaerE1gM4tdbsVvpRuIqW3deh0H9CB1mgJ70kNxuaUR2gLIJWCd7nkoAgp5cfIDcsxuvfIX2zz4sxddPp1-eo4PYuxwlUXaI9tqrzr6AGq5VL723_gUXYEfz
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+meta-analysis+of+everolimus-eluting+stents+versus+sirolimus-eluting+stents+and+paclitaxel-eluting+stents+in+diabetic+patients&rft.jtitle=Journal+of+cardiothoracic+surgery&rft.au=Ouyang%2C+Hang&rft.au=Zeng%2C+Xuehui&rft.au=Zhang%2C+Chunlei&rft.au=Song%2C+Linli&rft.date=2021-04-17&rft.pub=BioMed+Central&rft.eissn=1749-8090&rft.volume=16&rft.spage=1&rft_id=info:doi/10.1186%2Fs13019-021-01452-8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1749-8090&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1749-8090&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1749-8090&client=summon